Neuronal protection by cerium oxide nanoparticles
First Claim
Patent Images
1. A method of treating a subject identified as at risk of developing a neurodegenerative disease, comprising:
- administering a therapeutically effective amount of cerium oxide nanoparticles (CeO2NPs) to the subject, wherein the cerium oxide nanoparticles scavenge reactive oxygen species (ROS) and reactive nitrogen species (RNS) in the subject;
wherein the cerium oxide nanoparticles comprise more Ce3+ than Ce4+;
wherein the patient at risk exhibits symptoms comprising at least one of the following;
amyloid plaques in the brain or increased beta-amyloid deposits, neurofibrillary tangles (NFTs) in the brain, an atrophic brain region, atrophy of the hippocampus, increase in brain ventricle size, elevated levels of tau and/or amyloid beta proteins in cerebral spinal fluid, loss of function in the temporal lobe, cognitive deficiencies in memory, language, perceptual skills, attention, constructive abilities, orientation, problem solving, and/or functional abilities.
1 Assignment
0 Petitions
Accused Products
Abstract
A method of treating a subject with elevated levels of peroxynitrite includes administering a therapeutically effective amount of cerium oxide nanoparticles to the subject, wherein the cerium oxide nanoparticles reduce the level of peroxynitrite in the subject.
65 Citations
7 Claims
-
1. A method of treating a subject identified as at risk of developing a neurodegenerative disease, comprising:
administering a therapeutically effective amount of cerium oxide nanoparticles (CeO2NPs) to the subject, wherein the cerium oxide nanoparticles scavenge reactive oxygen species (ROS) and reactive nitrogen species (RNS) in the subject;
wherein the cerium oxide nanoparticles comprise more Ce3+ than Ce4+;
wherein the patient at risk exhibits symptoms comprising at least one of the following;
amyloid plaques in the brain or increased beta-amyloid deposits, neurofibrillary tangles (NFTs) in the brain, an atrophic brain region, atrophy of the hippocampus, increase in brain ventricle size, elevated levels of tau and/or amyloid beta proteins in cerebral spinal fluid, loss of function in the temporal lobe, cognitive deficiencies in memory, language, perceptual skills, attention, constructive abilities, orientation, problem solving, and/or functional abilities.- View Dependent Claims (2, 3, 4, 5, 6, 7)
Specification